在坦桑尼亚比较含吡丙醚-拟除虫菊酯、虫螨腈-拟除虫菊酯或增效醚-拟除虫菊酯的长效杀虫蚊帐与仅含拟除虫菊酯蚊帐抗疟效果:四臂单盲整群随机试验最终年结果
在坦桑尼亚开展四臂单盲整群随机试验,84个群组分配至标准拟除虫菊酯蚊帐、虫螨腈-拟除虫菊酯蚊帐、吡丙醚-拟除虫菊酯蚊帐或增效醚-拟除虫菊酯蚊帐。36个月时儿童疟疾感染率:标准拟除虫菊酯组37.4%,虫螨腈-拟除虫菊酯组22.8%(OR 0.57,95%CI 0.38-0.86;p=0.0069),增效醚-拟除虫菊酯组32.2%(OR 0.95,95%CI 0.64-1.42;p=0.80),吡丙醚-拟除虫菊酯组28.8%(OR 0.82,95%CI 0.55-1.23;p=0.34)。
要点
- 36个月时虫螨腈-拟除虫菊酯蚊帐组疟疾感染率低于标准拟除虫菊酯蚊帐组(OR 0.57,95%CI 0.38-0.86)。
- 增效醚-拟除虫菊酯蚊帐组与标准拟除虫菊酯蚊帐组无显著差异(OR 0.95,95%CI 0.64-1.42;p=0.80)。
- 吡丙醚-拟除虫菊酯蚊帐组与标准拟除虫菊酯蚊帐组无显著差异(OR 0.82,95%CI 0.55-1.23;p=0.34)。
核心结论
- 尽管覆盖率低,虫螨腈-拟除虫菊酯长效杀虫蚊帐在3年使用寿命内提供的抗疟保护效果优于标准拟除虫菊酯长效杀虫蚊帐。
- 需要适当的蚊帐更换策略以维持足够使用率,从而最大化这些蚊帐的全部潜力。
研究设计与样本
- 四臂单盲整群随机对照试验的第三年随访,于2021年7月14日至2022年2月10日在坦桑尼亚Misungwi开展。
- 采用限制性随机化将84个群组按1:1:1:1分配至标准拟除虫菊酯蚊帐(参照)、虫螨腈-拟除虫菊酯蚊帐、吡丙醚-拟除虫菊酯蚊帐或增效醚-拟除虫菊酯蚊帐组,每户每两人发放一顶蚊帐。
- 在群组核心区域同意参与的家庭中收集数据,纳入至少有一名6月龄至15岁永久居住儿童的家庭;排除访问时无人在家、居住在群组缓冲区、无成年照护者可提供知情同意或合格儿童病情严重者。
- 现场工作人员和研究参与者对分组设盲,数据分析人员不设盲;本文报告36个月时儿童疟疾感染患病率的次要结局,采用意向性分析。
- 试验注册于ClinicalTrials.gov(NCT03554616),现已完成。
主要发现
- 分配后36个月时,研究蚊帐总体使用率为1023/4587人(22.3%)。
- 标准拟除虫菊酯蚊帐组疟疾感染率为407/1088例参与者(37.4%)。
- 虫螨腈-拟除虫菊酯蚊帐组疟疾感染率为261/1145例参与者(22.8%),相比标准拟除虫菊酯蚊帐组OR 0.57(95%CI 0.38-0.86;p=0.0069)。
- 增效醚-拟除虫菊酯蚊帐组疟疾感染率为338/1048例参与者(32.2%),相比标准拟除虫菊酯蚊帐组OR 0.95(95%CI 0.64-1.42;p=0.80)。
- 吡丙醚-拟除虫菊酯蚊帐组疟疾感染率为302/1050例参与者(28.8%),相比标准拟除虫菊酯蚊帐组OR 0.82(95%CI 0.55-1.23;p=0.34)。
关键数值与推荐
- 世界卫生组织(WHO)近期建议在疟疾病媒对拟除虫菊酯耐药的地区使用含两种活性成分的新型长效杀虫蚊帐,该政策基于本试验前2年证据。
临床怎么用
- 作者认为,合适的蚊帐更换策略以维持足够使用率是必要的,从而最大化这些蚊帐的全部潜力。
局限性
- 覆盖率低(36个月时研究蚊帐总体使用率为1023/4587人,22.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New classes of long-lasting insecticidal nets (LLINs) containing two active ingredients have been recently recommended by WHO in areas where malaria vectors are resistant to pyrethroids. This policy was based on evidence generated by the first 2 years of our recently published trial in Tanzania. In this Article, we report the final third-year trial findings, which are necessary for assessing the long-term effectiveness of new classes of LLIN in the community and the replacement intervals required. METHODS: A third year of follow-up of a four-arm, single-blind, cluster-randomised controlled trial of dual active ingredient LLINs was conducted between July 14, 2021, and Feb 10, 2022, in Misungwi, Tanzania. Restricted randomisation was used to assign 84 clusters to the four LLIN groups (1:1:1:1) to receive either standard pyrethroid (PY) LLINs (reference), chlorfenapyr-PY LLINs, pyriproxyfen-PY LLINs, or piperonyl butoxide (PBO)-PY LLINs. All households received one LLIN for every two people. Data collection was done in consenting households in the cluster core area with at least one child between 6 months and 15 years of age who permanently resided in the selected household. Exclusion criteria were householders absent during the visit, living in the cluster buffer area, no adult caregiver capable of giving informed consent, or eligible children who were severely ill. Field staff and study participants were masked to allocation, and those analysing data were not. The primary 24-month endpoint was reported previously; here, we present the secondary outcome, malaria infection prevalence in children at 36 months post LLIN distribution, reported in the intention-to-treat analysis. The trial was registered with ClinicalTrials.gov (NCT03554616) and is now complete. FINDINGS: Overall usage of study nets was 1023 (22·3%) of 4587 people at 36 months post distribution. In the standard PY LLIN group, malaria infection was prevalent in 407 (37·4%) of 1088 participants, compared with 261 (22·8%) of 1145 in the chlorfenapyr-PY LLIN group (odds ratio 0·57, 95% CI 0·38-0·86; p=0·0069), 338 (32·2%) of 1048 in the PBO-PY LLIN group (0·95, 0·64-1·42; p=0·80), and 302 (28·8%) of 1050 in the pyriproxyfen-PY LLIN group (0·82, 0·55-1·23; p=0·34). None of the participants or caregivers reported side-effects. INTERPRETATION: Despite low coverage, the protective efficacy against malaria offered by chlorfenapyr-PY LLINs was superior to that provided by standard PY LLINs over a 3-year LLIN lifespan. Appropriate LLIN replacement strategies to maintain adequate usage of nets will be necessary to maximise the full potential of these nets. FUNDING: Department for International Development, UK Medical Research Council, Wellcome Trust, Department of Health and Social Care, and Bill & Melinda Gates Foundation via the Innovative Vector Control Consortium.
引用
- Mosha JF, Matowo NS, Kulkarni MA, et al. Effectiveness of long-lasting insecticidal nets with pyriproxyfen-pyrethroid, chlorfenapyr-pyrethroid, or piperonyl butoxide-pyrethroid versus pyrethroid only against malaria in Tanzania: final-year results of a four-arm, single-blind, cluster-randomised trial. Lancet Infect Dis. 2023. PMID: 37776879. doi:10.1016/S1473-3099(23)00420-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。